伊利諾大學(xué)芝加哥分校(University of Illinois at Chicago)的研究人員發(fā)現(xiàn),，在人類(lèi)卵巢癌細(xì)胞中有一個(gè)RNA的結(jié)合蛋白,，PTB(polypyrimidine tract-binding protein)有過(guò)度表現(xiàn)的現(xiàn)象，William Beck 及Xiaolong He教授的研究團(tuán)隊(duì)利用RNAi的方法使這個(gè)蛋白不表現(xiàn),，竟然發(fā)現(xiàn)能減少人類(lèi)卵巢癌細(xì)胞的生長(zhǎng)與侵入(invasiveness),。此研究成果發(fā)表于Oncogene期刊。
事實(shí)上,，卵巢癌是一個(gè)沉默的殺手,，患者常在發(fā)現(xiàn)時(shí)已經(jīng)進(jìn)入了癌癥后期，如果能早期發(fā)現(xiàn)及治療大約有90%的機(jī)會(huì)可以存活超過(guò)五年,，但是,，很不幸的，大約只有19%的患者在早期發(fā)現(xiàn)此癥。根據(jù)美國(guó)癌癥學(xué)會(huì)(American Cancer Society) 的統(tǒng)計(jì),，2006年約有20,180位新增病例,，卻有15,310人死亡,。卵巢癌的致死性之所以居高不下主要有兩個(gè)原因,，其一是缺乏早期診斷的指標(biāo)，第二是后段的治療并不完善,。
為了要提高患者的存活率,，務(wù)必要找到卵巢癌早期診斷的指標(biāo)，而PTB看來(lái)就是一個(gè)重要的指標(biāo),。Beck說(shuō)：「這是第一次發(fā)現(xiàn)RNA的剪接因子(RNA splicing factor)能抑制腫瘤細(xì)胞的生長(zhǎng)及入侵,，相信仍有許多類(lèi)似的機(jī)制存在于細(xì)胞內(nèi)，能作為更多癌癥早期診斷或治療的指標(biāo),?！?/p>
(資料來(lái)源 : Bio.com)
部分英文原文：
Oncogene advance online publication 19 February 2007; doi: 10.1038/sj.onc.1210307
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro
X He1,2, M Pool3, K M Darcy4, S B Lim2, N Auersperg5, J S Coon3 and W T Beck1,2
1Gynecologic Oncology Group (GOG) Core Laboratory in Molecular Pharmacology, University of Illinois at Chicago, Chicago, IL, USA
2Department of Biopharmaceutical Sciences, College of Pharmacy, and Cancer Center, University of Illinois at Chicago, Chicago, IL, USA
3Department of Pathology, Rush University Medical Center, Chicago, IL, USA
4GOG Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA
5Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
Correspondence: Dr WT Beck, Department of Biopharmaceutical Sciences (MC865), 833 South Wood Street, University of Illinois at Chicago, Chicago, IL 60612, USA. E-mail: [email protected]
Received 28 July 2006; Revised 26 December 2006; Accepted 1 January 2007; Published online 19 February 2007.
